BR112015006798A2 - vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico - Google Patents
vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleicoInfo
- Publication number
- BR112015006798A2 BR112015006798A2 BR112015006798A BR112015006798A BR112015006798A2 BR 112015006798 A2 BR112015006798 A2 BR 112015006798A2 BR 112015006798 A BR112015006798 A BR 112015006798A BR 112015006798 A BR112015006798 A BR 112015006798A BR 112015006798 A2 BR112015006798 A2 BR 112015006798A2
- Authority
- BR
- Brazil
- Prior art keywords
- mva virus
- virus
- genome
- mva
- producing
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 13
- 241000700618 Vaccinia virus Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 238000012258 culturing Methods 0.000 title 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/069256 WO2014048500A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015006798A2 true BR112015006798A2 (pt) | 2017-11-21 |
Family
ID=46982581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015006798A BR112015006798A2 (pt) | 2012-09-28 | 2012-09-28 | vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9732325B2 (https=) |
| EP (1) | EP2900810B1 (https=) |
| JP (1) | JP2015535687A (https=) |
| CN (1) | CN104812894B (https=) |
| AU (1) | AU2012391162A1 (https=) |
| BR (1) | BR112015006798A2 (https=) |
| CA (1) | CA2885240A1 (https=) |
| DK (1) | DK2900810T3 (https=) |
| IN (1) | IN2015DN02335A (https=) |
| MX (1) | MX2015003687A (https=) |
| RU (1) | RU2015115898A (https=) |
| WO (1) | WO2014048500A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3052895A1 (en) | 2017-02-23 | 2018-08-30 | Probiogen Ag | Vaccinia virus vectors related to modified vaccinia ankara (mva) with extensive genomic symmetries |
| EP3703723A4 (en) | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
| CN108371715A (zh) * | 2018-01-03 | 2018-08-07 | 肖小林 | 一种病毒的靶向性防治药物 |
| CN112512569A (zh) * | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| US11999975B2 (en) | 2018-07-04 | 2024-06-04 | Probiogen Ag | Method for purifying an enveloped virus |
| TW202227621A (zh) | 2020-11-19 | 2022-07-16 | 美商凱立凡爾免疫治療股份有限公司 | 重塑腫瘤微環境的溶瘤免疫療法 |
| WO2023128672A1 (ko) * | 2021-12-29 | 2023-07-06 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| EP2363493B1 (en) * | 2003-02-20 | 2012-11-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
-
2012
- 2012-09-28 WO PCT/EP2012/069256 patent/WO2014048500A1/en not_active Ceased
- 2012-09-28 JP JP2015533460A patent/JP2015535687A/ja active Pending
- 2012-09-28 EP EP12769398.4A patent/EP2900810B1/en active Active
- 2012-09-28 CA CA2885240A patent/CA2885240A1/en not_active Abandoned
- 2012-09-28 DK DK12769398.4T patent/DK2900810T3/en active
- 2012-09-28 BR BR112015006798A patent/BR112015006798A2/pt not_active IP Right Cessation
- 2012-09-28 IN IN2335DEN2015 patent/IN2015DN02335A/en unknown
- 2012-09-28 US US14/431,814 patent/US9732325B2/en active Active
- 2012-09-28 MX MX2015003687A patent/MX2015003687A/es unknown
- 2012-09-28 AU AU2012391162A patent/AU2012391162A1/en not_active Abandoned
- 2012-09-28 RU RU2015115898A patent/RU2015115898A/ru not_active Application Discontinuation
- 2012-09-28 CN CN201280077370.4A patent/CN104812894B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150299666A1 (en) | 2015-10-22 |
| US9732325B2 (en) | 2017-08-15 |
| RU2015115898A (ru) | 2016-11-20 |
| WO2014048500A1 (en) | 2014-04-03 |
| CN104812894A (zh) | 2015-07-29 |
| MX2015003687A (es) | 2015-06-15 |
| CN104812894B (zh) | 2021-10-22 |
| IN2015DN02335A (https=) | 2015-08-28 |
| EP2900810A1 (en) | 2015-08-05 |
| JP2015535687A (ja) | 2015-12-17 |
| CA2885240A1 (en) | 2014-04-03 |
| EP2900810B1 (en) | 2019-02-20 |
| DK2900810T3 (en) | 2019-04-29 |
| AU2012391162A1 (en) | 2015-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015006798A2 (pt) | vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| WO2012177924A3 (en) | Influenza virus mutants and uses therefor | |
| BRPI0712158B8 (pt) | processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada | |
| BRPI1015053A2 (pt) | partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina | |
| EP4349405A3 (en) | Respiratory virus vaccines | |
| WO2007048089A3 (en) | Multi-plasmid system for the production of influenza virus | |
| MX2018004918A (es) | Vacuna del virus herpes simple. | |
| HK1225631A1 (zh) | 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法 | |
| BR112014027736A2 (pt) | produção de partícula semelhante a rotavírus em plantas | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| UA113448C2 (xx) | Везикули, які містять епідермальний фактор росту і його композиції | |
| EA201001045A1 (ru) | Модифицированный вирус гриппа | |
| AU2007240448A8 (en) | Methods and compositions for expressing negative-sense viral RNA in canine cells | |
| BR112012028711A2 (pt) | métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit | |
| MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
| BR112015006763B1 (pt) | Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante | |
| MX2011012312A (es) | Vacuna universal para influenza basada en virus vaccinia ankara (mva) modificado recombinante. | |
| MX349294B (es) | Formulaciones virales liofilizadas. | |
| BR112014007474A2 (pt) | aumento de rendimento de partícula tipo vírus em plantas | |
| CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| BR112014017242A8 (pt) | vlps contendo hpv l2 imunogênico e composições e métodos relacionados | |
| WO2006063053A3 (en) | Methods of producing influenza vaccine compositions | |
| BR112015024391A2 (pt) | mutante de proteína, capsídeo, método para melhorar a estabilidade de um capsídeo, molécula de ácido nucleico isolada, célula hospedeira, micro-organismo recombinante carreador vivo, vacina, uso de um mutante da proteína vp2, e, métodos para preparar uma vacina e um mutante da proteína | |
| BR112012022292A2 (pt) | método para produção da proteína recombinante interferon solúvel sem desnaturação. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |